中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2008年
4期
268-271
,共4页
宋晓红%张罗%韩德民%王奎吉%王鸿%张伟
宋曉紅%張囉%韓德民%王奎吉%王鴻%張偉
송효홍%장라%한덕민%왕규길%왕홍%장위
羟甲唑啉%鼻黏膜%上皮细胞%纤毛
羥甲唑啉%鼻黏膜%上皮細胞%纖毛
간갑서람%비점막%상피세포%섬모
Oxymetazoline%Nasal mucosa%Epithelial cells%Cilia
目的 观察不同浓度盐酸羟甲唑啉对体外培养的人钩突黏膜纤毛细胞纤毛运动的影响.方法采用组织块培养法,观察在加有羟乙基哌嗪乙磺酸[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid,HEPES]的Hank平衡盐溶液(Hank balanced salt solution,HBSS)、0.25、0.50、1.00和2.00g/L的盐酸羟甲唑啉作用下,体外培养人鼻腔纤毛细胞的纤毛摆动频率(ciliarybeat frequency,CBF),并进行配对分析.结果 ① CBF在HBSS中20 min内无显著性变化(F=0.098,P=1.00);②0.25g/L盐酸羟甲唑啉组在20 min内与加药前CBF无明显变化,差异无统计学意义(F=0.124,P=1.00);③0.50g/L盐酸羟甲唑啉组与1.00g/L盐酸羟甲唑啉组类似,CBF轻微升高,并在1~2min内达到高峰,保持3~4min后,CBF开始缓慢下降,在测量最后达到最低值,但0.50g/L盐酸羟甲唑啉组与加药前相比,差异无统计学意义(F=2.94,P=0.05);1.00g/L盐酸羟唑啉组较加药前CBF降低,加药16 min后,差异有统计学意义(F=3.78,P=0.00);④2.00g/L盐酸羟甲唑啉组CBF在最初3min保持稳定,然后持续下降,差异有统计学意义(F=5.69,P=0.00);⑤各组在加药后的最大增加值,差异无统计学意义(F=0.85,P=0.50);加药后的最大下降值在1.00和2.00g/L的CBF明显降低,差异有统计学意义(F=23.74,P=0.00).结论 0.25~2.00g/L的盐酸羟甲唑啉对体外培养的人鼻腔纤毛细胞的纤毛运动存在一定浓度依赖性的抑制作用,且随着药物浓度的增加,抑制作用逐渐增强;0.50g/L盐酸羟甲唑啉可能更适用于临床应用.
目的 觀察不同濃度鹽痠羥甲唑啉對體外培養的人鉤突黏膜纖毛細胞纖毛運動的影響.方法採用組織塊培養法,觀察在加有羥乙基哌嗪乙磺痠[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid,HEPES]的Hank平衡鹽溶液(Hank balanced salt solution,HBSS)、0.25、0.50、1.00和2.00g/L的鹽痠羥甲唑啉作用下,體外培養人鼻腔纖毛細胞的纖毛襬動頻率(ciliarybeat frequency,CBF),併進行配對分析.結果 ① CBF在HBSS中20 min內無顯著性變化(F=0.098,P=1.00);②0.25g/L鹽痠羥甲唑啉組在20 min內與加藥前CBF無明顯變化,差異無統計學意義(F=0.124,P=1.00);③0.50g/L鹽痠羥甲唑啉組與1.00g/L鹽痠羥甲唑啉組類似,CBF輕微升高,併在1~2min內達到高峰,保持3~4min後,CBF開始緩慢下降,在測量最後達到最低值,但0.50g/L鹽痠羥甲唑啉組與加藥前相比,差異無統計學意義(F=2.94,P=0.05);1.00g/L鹽痠羥唑啉組較加藥前CBF降低,加藥16 min後,差異有統計學意義(F=3.78,P=0.00);④2.00g/L鹽痠羥甲唑啉組CBF在最初3min保持穩定,然後持續下降,差異有統計學意義(F=5.69,P=0.00);⑤各組在加藥後的最大增加值,差異無統計學意義(F=0.85,P=0.50);加藥後的最大下降值在1.00和2.00g/L的CBF明顯降低,差異有統計學意義(F=23.74,P=0.00).結論 0.25~2.00g/L的鹽痠羥甲唑啉對體外培養的人鼻腔纖毛細胞的纖毛運動存在一定濃度依賴性的抑製作用,且隨著藥物濃度的增加,抑製作用逐漸增彊;0.50g/L鹽痠羥甲唑啉可能更適用于臨床應用.
목적 관찰불동농도염산간갑서람대체외배양적인구돌점막섬모세포섬모운동적영향.방법채용조직괴배양법,관찰재가유간을기고진을광산[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid,HEPES]적Hank평형염용액(Hank balanced salt solution,HBSS)、0.25、0.50、1.00화2.00g/L적염산간갑서람작용하,체외배양인비강섬모세포적섬모파동빈솔(ciliarybeat frequency,CBF),병진행배대분석.결과 ① CBF재HBSS중20 min내무현저성변화(F=0.098,P=1.00);②0.25g/L염산간갑서람조재20 min내여가약전CBF무명현변화,차이무통계학의의(F=0.124,P=1.00);③0.50g/L염산간갑서람조여1.00g/L염산간갑서람조유사,CBF경미승고,병재1~2min내체도고봉,보지3~4min후,CBF개시완만하강,재측량최후체도최저치,단0.50g/L염산간갑서람조여가약전상비,차이무통계학의의(F=2.94,P=0.05);1.00g/L염산간서람조교가약전CBF강저,가약16 min후,차이유통계학의의(F=3.78,P=0.00);④2.00g/L염산간갑서람조CBF재최초3min보지은정,연후지속하강,차이유통계학의의(F=5.69,P=0.00);⑤각조재가약후적최대증가치,차이무통계학의의(F=0.85,P=0.50);가약후적최대하강치재1.00화2.00g/L적CBF명현강저,차이유통계학의의(F=23.74,P=0.00).결론 0.25~2.00g/L적염산간갑서람대체외배양적인비강섬모세포적섬모운동존재일정농도의뢰성적억제작용,차수착약물농도적증가,억제작용축점증강;0.50g/L염산간갑서람가능경괄용우림상응용.
Objective To investigate the effects of oxymetazoline hydrochloride on ex vivo human nasal cilia movement.Methods Ciliary beat frequency (CBF) of cultured human nasal epithelial cells was measured by high-speed digital microscopy in HBSS and oxymetazoline hydrochloride of different concentrations in 20 minutes.Results CBF of cultured nasal epithelial cells in HBSS and 0.25 g/L oxymetazoline hydrochloride did not show significant changes in 20 minutes (F=0.098,P=1.00).However,in 0.50g/L and 1.00g/L oxymetazoline hydrochloride,CBF increased slightly in 3-4 minutes and reached the apex,then decreased gradually.At the end of observation,CBF showed no significant difference in 0.50g/L,(F=2.94,P=0.05) but there was a significant lower CBF in 1.00g/L.In the first 3 minutes,the CBF in 2.00g/L oxymetazoline hydrochloride was stable,and then slowed gradually.After 16 minutes,there was significant difference.In initial,the highest normalized CBF of each group showed no significant difference.However,the lowest normalized CBF of 1.00 and 2.00g/L oxymetazoline hydrochloride showed a significant difference with HBSS,0.25 and 0.50g/L oxymetazoline hydrochloride.Conclusions Oxymetazoline had a concentration-dependent inhibitory effect on cultured human nasal CBF from 0.25 to 2.00g/L.The inhibitory effect increasedwith the concentration going up.Oxymetazoline hydrochloride of 0.50g/L might be the optimal choice for clinical application.